Metabasis Type 2 Diabetes Candidate Successful In Phase IIa Study
This article was originally published in The Pink Sheet Daily
Executive Summary
San Diego company wants to partner the second-generation gluconeogenesis inhibitor.
You may also be interested in...
Metabasis Reports Disappointments On Two Pipeline Candidates
Phase IIb trial of a type 2 diabetes candidate fails to show efficacy over metformin, and Schering-Plough also returns rights to hepatitis b candidate pradefovir.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.
MADIT-CRT Data Support Expanded Cardiac Resynchronization Market
The results show that cardiac resynchronization defibrillators "slow the progression of heart failure in asymptomatic and mildly symptomatic patients," potentially expanding the market by $600 million.